ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, Voi M, Wu C, Degtyarev E, Aimone P, Singh S (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Neuroendocrinology Karger

Book Volume: 106

Pages Range: 218-218

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Novartis AG

Switzerland (CH) European Institute of Oncology / Istituto Europeo di Oncologia (IEO)

Italy (IT) University of California San Francisco (UCSF)

United States (USA) (US) City of Hope Medical Center

United States (USA) (US) University of Texas MD Anderson Cancer Center

United States (USA) (US) Sunnybrook Health Sciences Centre

Canada (CA) H. Lee Moffitt Cancer Center & Research Institute

United States (USA) (US) Beaujon Hospital / Hôpital Beaujon

France (FR)

How to cite

APA:

Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J., Bergsland, E.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).

MLA:

Yao, J. C., et al. "ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment." 2018. 218-218.

BibTeX: Download